Efficacy of the investigational mTOR kinase inhibitor MLN0128/INK128 in models of B-cell acute lymphoblastic leukemia
Published 2012 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Efficacy of the investigational mTOR kinase inhibitor MLN0128/INK128 in models of B-cell acute lymphoblastic leukemia
Authors
Keywords
-
Journal
LEUKEMIA
Volume 27, Issue 3, Pages 586-594
Publisher
Springer Nature
Online
2012-10-23
DOI
10.1038/leu.2012.276
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Targeting TOR dependence in cancer
- (2015) Oncotarget
- Will PI3K pathway inhibitors be effective as single agents in patients with cancer?
- (2015) Joan T. Garrett et al. Oncotarget
- Phase I safety, pharmacokinetic, and pharmacodynamic study of the oral phosphatidylinositol-3-kinase and mTOR inhibitor BGT226 in patients with advanced solid tumors
- (2012) B. Markman et al. ANNALS OF ONCOLOGY
- Dual mTORC1/2 and HER2 Blockade Results in Antitumor Activity in Preclinical Models of Breast Cancer Resistant to Anti-HER2 Therapy
- (2012) C. Garcia-Garcia et al. CLINICAL CANCER RESEARCH
- Abstract B148: INK128 is a potent and selective TORC1/2 inhibitor with broad oral antitumor activity
- (2012) K. Jessen et al. MOLECULAR CANCER THERAPEUTICS
- The translational landscape of mTOR signalling steers cancer initiation and metastasis
- (2012) Andrew C. Hsieh et al. NATURE
- Dual mTORC2/mTORC1 Targeting Results in Potent Suppressive Effects on Acute Myeloid Leukemia (AML) Progenitors
- (2011) J. K. Altman et al. CLINICAL CANCER RESEARCH
- Next-generation mTOR inhibitors in clinical oncology: how pathway complexity informs therapeutic strategy
- (2011) Seth A. Wander et al. JOURNAL OF CLINICAL INVESTIGATION
- GDC-0980 Is a Novel Class I PI3K/mTOR Kinase Inhibitor with Robust Activity in Cancer Models Driven by the PI3K Pathway
- (2011) J. J. Wallin et al. MOLECULAR CANCER THERAPEUTICS
- Pushing the Envelope in the mTOR Pathway: The Second Generation of Inhibitors
- (2011) E. Vilar et al. MOLECULAR CANCER THERAPEUTICS
- Inhibition of PI3K/mTOR pathways in glioblastoma and implications for combination therapy with temozolomide
- (2011) G. Prasad et al. NEURO-ONCOLOGY
- Target of Rapamycin Signaling in Leukemia and Lymphoma
- (2010) C. Vu et al. CLINICAL CANCER RESEARCH
- Induction of autophagy-dependent necroptosis is required for childhood acute lymphoblastic leukemia cells to overcome glucocorticoid resistance
- (2010) Laura Bonapace et al. JOURNAL OF CLINICAL INVESTIGATION
- Perspectives on inhibiting mTOR as a future treatment strategy for hematological malignancies
- (2010) N Chapuis et al. LEUKEMIA
- Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor
- (2010) Matthew R Janes et al. NATURE MEDICINE
- mTOR: from growth signal integration to cancer, diabetes and ageing
- (2010) Roberto Zoncu et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Critical roles for mTORC2- and rapamycin-insensitive mTORC1-complexes in growth and survival of BCR-ABL-expressing leukemic cells
- (2010) Nathalie Carayol et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Rapamycin inhibits mTORC1, but not completely
- (2009) Carson C. Thoreen et al. Autophagy
- Targeting the phosphoinositide 3-kinase pathway in cancer
- (2009) Pixu Liu et al. NATURE REVIEWS DRUG DISCOVERY
- NVP-BEZ235, a Dual PI3K/mTOR Inhibitor, Prevents PI3K Signaling and Inhibits the Growth of Cancer Cells with Activating PI3K Mutations
- (2008) V. Serra et al. CANCER RESEARCH
- Ablation of PI3K blocks BCR-ABL leukemogenesis in mice, and a dual PI3K/mTOR inhibitor prevents expansion of human BCR-ABL+ leukemia cells
- (2008) Michael G. Kharas et al. JOURNAL OF CLINICAL INVESTIGATION
- Acute lymphoblastic leukaemia
- (2008) Ching-Hon Pui et al. LANCET
- Targeting survival cascades induced by activation of Ras/Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways for effective leukemia therapy
- (2008) J A McCubrey et al. LEUKEMIA
- Contributions of the Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways to leukemia
- (2008) L S Steelman et al. LEUKEMIA
- Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity
- (2008) S.-M. Maira et al. MOLECULAR CANCER THERAPEUTICS
- Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases
- (2008) Beth Apsel et al. Nature Chemical Biology
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started